| 摘要 |
<p>The present invention relates to methods for screening for therapeutics on the basis of biomarkers responsive to treatment with thiazolidinediones, in particular therapeutics having activities analogous to thiazolidinediones. Such therapeutics may be useful, for example, in therapy of Type II diabetes, insulin resistance, obesity, impaired glucose tolerance, metabolic syndrome (syndrome x), cardiovascular diseases, atherosclerosis and dyslipidemia. Furthermore, the invention relates to methods for testing whether an individual will benefit from treatment with the afore mentioned therapeutics.
The biomarkers are selected from Fn14, HMGA1, apelin, fragments and variants thereof.</p> |
